A Critical Nexus:The Clinician and the Researcher.
14 July 2020
As clinician researchers, with busy clinical loads, our greatest challenge is ﬁnding time to engage deeply in the science. But it is necessary to deliver on our research goals.
The nexus between the clinician and the researcher is critical and underpins successful cancer research.
Embedded in every academic clinical cancer service there needs to be a vibrant program of research, which includes basic and translational research. Similarly, embedded in every cancer-related research laboratory, strong links to clinicians at the front line are essential. By working together, clinicians and scientists can gain insights beyond those easily achieved individually.
The clinician and scientist approach the cancer challenge from differing perspectives. Clinicians have a global perspective of the disease enabling them to identify what needs to change for maximal impact. Scientists tend to have a meticulous understanding of speciﬁc steps within complex biological systems - breaking the big picture into smaller parts, thus identifying opportunities for manipulation. Neither can successfully achieve the goal without the other.
This symbiotic relationship is well illustrated by modern cancer immunotherapy. For decades, clinicians recognised that immune manifestations correlated with good outcomes, but it was not until James Allison and Tasuko Honjo identiﬁed critical checkpoints in immune regulation that the opportunity to harness the immune system against cancer was realised. Now, checkpoint inhibitor drug therapies have transformed the cancer ﬁeld, highlighting what can be achieved when clinicians and scientists build upon their respective insights.
Article by Professor Georgina Long AO and Profesor Richard Scolyer, Melanoma Institute Australia and University of Sydney.
Read the full article Voices:Translating Basic Cancer Discoveries to the Clinic in Cancer Cell 37 here
The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.
Drug therapy set to become standard treatment in high-risk early stage patients to stop disease spread
Prof Long AO has been recognised by Australian Academy of Health and Medical Sciences for her transformative work advancing melanoma treatments.
COVID restrictions continue to impact fundraising for melanoma services in Riverina.
Ben Garrow lost his life to melanoma. In his honour his family has established a scholarship to support a PhD student whose work focuses on saving lives from melanoma.
More than 150 clinicians, researchers and MIA staff gathered online to share research highlights.
Independent researchers at The University of Sydney are seeking patient feedback.
A re-cap of the wonderful, and often very creative, community fundraising initiatives over the April to June quarter.
Our patients who donate their tissue samples and records to our research are helping to make a difference to the lives of future melanoma patients.
MIA researchers have recently been awarded two competitive funding grants, which will help facilitate their ground-breaking work in melanoma research.
Celebrate the 10th anniversary of Amie St Clair Melanoma at the Annual Ball in Wagga Wagga!
Postponed to early 2022. Melanoma survivor Matt Kean is doing a 1000km bike ride around the Riverina to increase awareness of melanoma and raise funds for Amie St Clair Melanoma - MIA. There are many ways you can be part of this life-changing ride!
Riverina patients gain access to potentially life saving immunotherapy treatment close to home.
MIA's Prof Scolyer has been appointed as an Officer (AO) of the Order of Australia.
In a breakthrough which could extend to the treatment of other cancers, a new immune checkpoint inhibitor has proven effective in helping save the lives of advanced melanoma patients.
Whilst our research and clinical teams are trialling new treatments to save lives, it is our nurses who are on the front line providing care and support.
The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.
Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.